期刊文献+

荧光原位杂交技术在骨髓增生异常综合征预后因素分析中的应用 被引量:2

Application of fluorescence in situ hybridization in the analysis of prognostic factors in patients with myelodysplastic syndrome
下载PDF
导出
摘要 目的探讨骨髓增生异常综合征(MDS)患者年龄、遗传学核型及是否转化为白血病等因素对预后的影响。方法对50例骨髓增生异常综合征患者进行常规细胞遗传学核型分析并对5、7、8号染色体进行荧光原位杂交(FISH)检测,运用单因素Cox回归模型分析年龄、遗传学核型及是否转化为白血病等因素对患者生存率的影响。结果 50例MDS患者中19例常规细胞遗传学核型分析法检出异常,30例患者经FISH检出异常,FISH法检出阳性率高于常规方法,差异有统计学意义(P<0.05)。Cox回归模型分析显示65岁以上患者、遗传学核型异常者、转化为白血病的患者死亡风险分别高于65岁以下患者、遗传学核型正常者、未转化为白血病的患者(P均小于0.05)。结论 FISH技术能敏感地检测出小克隆异常,运用常规细胞遗传学技术结合多种探针进行分析,能对MDS患者的诊断、转归及预后进行更为准确的判断。MDS患者的细胞遗传学核型异常及转归是影响患者预后的重要危险因素。 Objective To investigate the effects of several factors such as age,genetic karyotype,and the leukemia transformation on the prognosis in patients with myelodysplastic syndrome(MDS).Methods The routine genetic karyotype analysis and the method of fluorescence in situ hybridization(FISH) for chromosome 5,7,8 were used in 50 patients with MDS.The effects of age,genetic karyotype as well as leukemia transformation on prognosis were then studied by Cox regression singlevariate analysis.Results Nineteen abnormal genetic karyotype patients were found in 50 MDS patients,and 30 anomalous cases were detected by FISH.The positive rate of FISH was significantly higher than the genetic karyotype analysis,the difference was statistically significant(P0.05).It was showed by Cox regression analysis that patients with the age of more than 65 and abnormal genetic karyotype as well as those leukemia transformed cases have a high risk of death than the rest patients(P0.05).Conclusion The method of FISH can be used to detect abnormal clone cells sensitively.For MDS patients,the diagnosis and prognosis can be determined more exactly by combined using of routine genetic karyotype analysis and multi-probe detection.The abnormal cytogenetic karyotype and leukemia transformation are the key factors affecting the prognosis of MDS patients.
出处 《国际检验医学杂志》 CAS 2013年第13期1673-1675,共3页 International Journal of Laboratory Medicine
关键词 骨髓增生异常综合征 原位杂交 荧光 预后 myelodysplastic syndromes in situ hybridization fluorescence prognosis
  • 相关文献

参考文献13

二级参考文献85

  • 1王化泉,邵宗鸿,曹燕然,施均,刘鸿,白洁,涂梅峰,邢莉民,崔振珠,刘世和,孙娟,贾海蓉,杨天楹.染色体异常核型数量与骨髓增生异常综合征进展和预后相关性研究[J].中华血液学杂志,2006,27(1):28-31. 被引量:19
  • 2马力,李建勇,潘金兰,肖冰,钱思轩,陈丽娟,仇海荣,温丙昭,薛永权.多重荧光原位杂交技术检测急性髓系白血病复杂核型异常的价值[J].中华血液学杂志,2006,27(5):318-322. 被引量:5
  • 3肖志坚,郝玉书.骨髓增生异常综合征的治疗选择[J].中华内科杂志,2007,46(4):265-267. 被引量:7
  • 4张之南.血液学诊断及疗效标准[M].3版.北京:北京科技出版社,2007:157-163.
  • 5Acquaviva C, Gelsi-Boyer V, Birnbaum D. Myelodysplastic syndromes: lost between two states? Leukemia, 2010, 24.1.
  • 6Brunning RD, AO, Germing U, et al. Myelodysplastic syndromes/Neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon:IARC,2008, p. 88-93.
  • 7Komrokji RS, Zhang L, Bennett JM. Myelodysplastic syndromes classification and risk stratification. Hematol Oncol Clin N Am,2010,24:443.
  • 8Mufti GJ, Bennett JM, Goasguen J, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica, 2008, 93: 1712.
  • 9van de Loosdrecht AA, Alhan C, Bene MC, et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cyto metry in myelodysplastic syndromes. Haematologica, 2009,94:1124.
  • 10Peter Valent, Hans-Peter Horny, John M, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res, 2007,31 : 727.

共引文献25

同被引文献16

  • 1邱镜滢,赖悦云,柴晔,张艳,师岩,何琦,党辉,陆道培.306例骨髓增生异常综合征染色体核型的研究[J].中国实验血液学杂志,2004,12(4):455-459. 被引量:32
  • 2于明华,刘世和,邵英起,郝玉书,肖志坚.原发性骨髓增生异常综合征患者染色体核型与IPSS危度分组:FAB与WHO分型比较[J].中华血液学杂志,2004,25(8):482-485. 被引量:12
  • 3潘含章,陈志妹,楼基余,徐伟来,金洁.283例骨髓增生异常综合征染色体核型分析[J].浙江大学学报(医学版),2006,35(2):143-146. 被引量:8
  • 4Keith T, Araki Y,Ohyagi M,et al. Regulation of angiogenesis inthe bone marrow of myelodyspiastic syndromes transforming to o-vert leukaemia[J]. Br J Haematol,2007 ,137(3) : 206-215.
  • 5Vardiman JW,Thiele J, Arber DA,et al. The 2008 revision of theWorld Health Organization (WHO) classification of myeloid neo-plasms and acute leukemia: rationale and important changes[J].Blood,2009,114(5):937-951.
  • 6Malcovati L, Della Porta M G, Strupp C, et al. Impact of the de-gree of anemia on the outcome of patients with myelodyspiasticsyndrome and its integration into the WHO classification-basedPrognostic Scoring System (WPSS) [J], Haematologica, 2011, 96(10):1433-1440.
  • 7Tang N.Wang L’Esko J,et al. Loss of HIF-la in endothelial cellsdisrupts a hypoxia-driven VEGF autocrine loop necessary for tu-morigenesis[J]. Cancer Cell,2004,6(5) :485-495.
  • 8Ghosh AK, Shanafelt TD, Cimmino A, et al. Aberrant regulationof pVHL levels by microRNA promotes the HIF/VEGF axis inCLL B cells[J]. Blood,2009 ,113(22) : 5568-5574.
  • 9Wang Y, Liu Y, Malek S N* et al. Targeting HIFla eliminatescancer stem cells in hematological malignancies [J]. Cell StemCell,2011,8(4) :399-411.
  • 10Rosen MD. Venkatesan H,Peltier HM, et al. Benzimidazole-2-pyrazole HIF prolyl 4-hydroxylase inhibitors as oral erythropoie-tin secretagogues[J]. ACS Med Chem Lett,2010,1 (9) :526-529.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部